{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T20:34:34Z","timestamp":1774816474179,"version":"3.50.1"},"reference-count":60,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, I.P.","award":["UIDP\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020"]}]},{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, I.P.","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}]},{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, I.P.","award":["LA\/P\/0140\/2020"],"award-info":[{"award-number":["LA\/P\/0140\/2020"]}]},{"name":"Associate Laboratory Institute for Health and Bioeconomy\u2014i4HB","award":["UIDP\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020"]}]},{"name":"Associate Laboratory Institute for Health and Bioeconomy\u2014i4HB","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}]},{"name":"Associate Laboratory Institute for Health and Bioeconomy\u2014i4HB","award":["LA\/P\/0140\/2020"],"award-info":[{"award-number":["LA\/P\/0140\/2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Pharmaceutical compounding is an important component of pharmacy practice despite its low prevalence. Several therapeutic needs can be met by a compounded medicine such as dosing adjusted for pediatric patients, special drug combinations, medicines for patients allergic to a given excipient, and medicines for orphan drugs not provided by the pharmaceutical industry. Examples of such applications are provided in this review. Adherence to medication is a critical public health issue as nonadherence to pharmacotherapy has been associated with adverse outcomes and higher costs of patient care. Adherence to therapy represents a key factor in the reduction in morbidity and mortality and optimization of the use of financial resources. The role of pharmaceutical compounding in promoting medication adherence is underexploited. The customization might represent a positive reinforcement of the initiation of the treatment, while implementation and persistence might also be favored in a pharmacy setting. However, studies addressing the influence of compounding in adherence promotion are lacking in the literature. The results of such studies could support health policies including proper regulatory framework, pharmacist training, and information to health care practitioners.<\/jats:p>","DOI":"10.3390\/ph15091091","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T01:50:51Z","timestamp":1661997051000},"page":"1091","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["The Role of Pharmaceutical Compounding in Promoting Medication Adherence"],"prefix":"10.3390","volume":"15","author":[{"given":"Maria","family":"Carvalho","sequence":"first","affiliation":[{"name":"Professional Compounding Centers of America (PCCA), Department of Research & Development, Houston, TX 77099, USA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-048X","authenticated-orcid":false,"given":"Isabel","family":"Almeida","sequence":"additional","affiliation":[{"name":"UCIBIO-REQUIMTE, MedTech, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"},{"name":"Associate Laboratory i4HB\u2014Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_2","unstructured":"Khan, R., and Socha-Dietrich, K. (2018). Investing in Medication Adherence Improves Health Outcomes and Health System Efficiency: Adherence to Medicines for Diabetes, Hypertension, and Hyperlipidaemia, Available online: https:\/\/www.oecd-ilibrary.org\/social-issues-migration-health\/investing-inmedication-adherence-improves-health-outcomes-and-health-systemefficiency_8178962c-en."},{"key":"ref_3","unstructured":"WHO (2013). Adherence to Long-Term Therapies: Evidence for Action, WHO."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2147\/PPA.S164819","article-title":"Adherence to chronic medication in older populations: Application of a common protocol among three European cohorts","volume":"12","author":"Menditto","year":"2018","journal-title":"Patient Prefer. Adherence"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Teixeira, A., Teixeira, M., Almeida, V., Gaio, R., Torres, T., Magina, S., Cunha, C., Lobo, J.M.S., and Almeida, I.F. (2021). Does the Vehicle Matter? Real-World Evidence on Adherence to Topical Treatment in Psoriasis. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13101539"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Menditto, E., Orlando, V., De Rosa, G., Minghetti, P., Musazzi, U.M., Cahir, C., Kurczewska-Michalak, M., Kardas, P., Costa, E., and Lobo, J.M.S. (2020). Patient Centric Pharmaceutical Drug Product Design\u2014The Impact on Medication Adherence. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12010044"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijpharm.2016.03.007","article-title":"Acceptability of oral solid medicines in older adults with and without dysphagia: A nested pilot validation questionnaire based observational study","volume":"512","author":"Liu","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3109\/15622975.2010.505663","article-title":"Patients\u2019 preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study","volume":"11","author":"Itter","year":"2010","journal-title":"World J. Boil. Psychiatry"},{"key":"ref_9","first-page":"46","article-title":"Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis","volume":"94","author":"Eastman","year":"2014","journal-title":"Cutis"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"s44","DOI":"10.25251\/skin.6.supp.44","article-title":"Vehicle Formulation Impacts Tolerability and Patient Preference: Comparison of Tretinoin Branded Lotion and Generic Cream","volume":"6","author":"Draelos","year":"2022","journal-title":"Ski. J. Cutan. Med."},{"key":"ref_11","unstructured":"De Carvalho, M.J.R. (2013). Extemporaneously Compounded Oral Medicines in European Hospital Pharmacies. [Ph.D. Thesis, (UCL) University College London]."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Allen, L.V. (2020). The Art, Science, and Technology of Pharmaceutical Compounding, APhA. [6th ed.].","DOI":"10.21019\/9781582123578"},{"key":"ref_13","first-page":"94","article-title":"New England Compounding Center Indictment","volume":"19","author":"Cabaleiro","year":"2015","journal-title":"Int. J. Pharm. Compd."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13181-020-00814-3","article-title":"Pharmaceutical Compounding: A History, Regulatory Overview, and Systematic Review of Compounding Errors","volume":"17","author":"Watson","year":"2020","journal-title":"J. Med. Toxicol."},{"key":"ref_15","unstructured":"Council of Europe (2013). Pharmaceutical Preparations. European Pharmacopoeia, Council of Europe. [7th ed.]."},{"key":"ref_16","unstructured":"Council of Europe (2019). Pharmaceutical Preparations. European Pharmacopoeia, Council of Europe. [10th ed.]."},{"key":"ref_17","unstructured":"CompoundingToday (2021, February 15). Editorial: What is Compounding Pharmacy, Part IV. Available online: https:\/\/compoundingtoday.com\/Newsletter\/Newsletter11_21.cfm."},{"key":"ref_18","unstructured":"United States Pharmacopeial Convention (2020). USP General Chapter <795> Pharmaceutical Compounding-Nonsterile Preparations. USP 43-NF 38 as of June 1, 2020, United States Pharmacopeial Convention."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1310\/hpj4907-615","article-title":"The Drug Quality and Security Act","volume":"49","author":"Gabay","year":"2014","journal-title":"Hosp. Pharm."},{"key":"ref_20","unstructured":"(2021, February 20). Public Law 113-54, 113th Congress, H.R. 3204: Drug Quality and Security Act, Available online: https:\/\/www.congress.gov\/113\/plaws\/publ54\/PLAW-113publ54.pdf."},{"key":"ref_21","unstructured":"FDA (2021, February 15). Registered Outsourcing Facilities, Available online: https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/registered-outsourcing-facilities."},{"key":"ref_22","unstructured":"United States Pharmacopeial Convention (2020). Compounding Compendium. Current with USP 43-NF 38 through Second Supplement, United States Pharmacopeial Convention."},{"key":"ref_23","unstructured":"United States Pharmacopeial Convention (2020). USP General Chapter <797> Pharmaceutical Compounding-Sterile Preparations. USP 43-NF 38 as of June 1, 2020, United States Pharmacopeial Convention."},{"key":"ref_24","unstructured":"United States Pharmacopeial Convention (2020). USP General Chapter <800> Hazardous Drugs-Handling in Healthcare Settings. USP 43-NF 38 as of June 1, 2020, United States Pharmacopeial Convention."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1310\/hpj5202-124","article-title":"Pharmacists and Pediatric Medication Adherence: Bridging the Gap","volume":"52","author":"Larochelle","year":"2017","journal-title":"Hosp. Pharm."},{"key":"ref_26","unstructured":"Paediatric Formulary Committee BNF for Children 2020\u20132021 (Online), BMJ Group, Pharmaceutical Press, and RCPCH Publications. Available online: https:\/\/ebookcentral.proquest.com\/."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ju\u00e1rez-Hern\u00e1ndez, J.E., and Carleton, B.C. (2022). Paediatric oral formulations: Why don\u2019t our kids have the medicines they need?. Br. J. Clin. Pharmacol., 1\u201312.","DOI":"10.1111\/bcp.15456"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"20200012","DOI":"10.1515\/pthp-2020-0012","article-title":"Development and characterization of paracetamol medicated lollipops","volume":"5","author":"Hejaz","year":"2020","journal-title":"Pharm. Technol. Hosp. Pharm."},{"key":"ref_29","first-page":"113","article-title":"Tetracycline Compound Troche","volume":"1","author":"Allen","year":"1997","journal-title":"Int. J. Pharm. Compd."},{"key":"ref_30","first-page":"395","article-title":"Tetracaine lollipops for the suppression of extreme gag reflex in dental patients","volume":"14","author":"Muller","year":"2013","journal-title":"Int. J. Pharm. Compd."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jpeds.2008.06.030","article-title":"Medicines for Children: A Matter of Taste","volume":"153","author":"Davies","year":"2008","journal-title":"J. Pediatrics"},{"key":"ref_32","unstructured":"(2021, February 16). FLAVORx Pediatric System. Available online: https:\/\/www.flavorx.com\/flavorx-pediatric-system\/."},{"key":"ref_33","unstructured":"Amos, S.R., Baker, C., and Gueye, Y. (2011, January 20\u201321). Improving the Palatability of Medications to Help Children be more Compliant. Proceedings of the 3rd European Paediatric Formulation Initiative (EuPFI) Conference: Formulating Better Medicines for Children, Poster Presentation, Strasbourg, France."},{"key":"ref_34","first-page":"482","article-title":"Compounding Challenges for Immunocompromised Patients","volume":"12","author":"McElhiney","year":"2008","journal-title":"Int. J. Pharm. Compd."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5055\/jom.2018.0425","article-title":"The Role of Transdermal Compounding in Opioid Safety","volume":"14","author":"Bucher","year":"2018","journal-title":"J. Opioid Manag."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/pme.12899","article-title":"Evaluation of the Percutaneous Absorption of Ketamine HCl, Gabapentin, Clonidine HCl, and Baclofen, in Compounded Transdermal Pain Formulations, Using the Franz Finite Dose Model","volume":"17","author":"Bassani","year":"2015","journal-title":"Pain Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.cgh.2019.10.029","article-title":"Prevalence and Characteristics of Dysphagia Based on a Population-Based Survey","volume":"18","author":"Adkins","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_38","first-page":"498","article-title":"Compliance to treatment in elderly dysphagic patients: Potential benefits of alternative dosage forms","volume":"11","author":"Bramwell","year":"2013","journal-title":"Int. J. Pharm. Compd."},{"key":"ref_39","first-page":"393","article-title":"The Difficulty of Opening Medicine Containers in Old Age: A Population-Based Study","volume":"27","author":"Beckman","year":"2005","journal-title":"Pharm. Weekbl. Sci. Ed."},{"key":"ref_40","unstructured":"CSS Health (2021, February 17). Medicine-On-Time. Available online: https:\/\/medicineontime.com\/."},{"key":"ref_41","first-page":"247","article-title":"Warfarin Personalized Dosage: Re-compounding for a More Suitable Therapy and Better Compliance","volume":"21","author":"Pellagatti","year":"2017","journal-title":"Int. J. Pharm. Compd."},{"key":"ref_42","unstructured":"Lonza (2021, February 16). Coni-Snap\u00ae Sprinkle Capsules. Available online: https:\/\/www.capsugel.com\/consumer-health-nutrition-products\/coni-snap-sprinkle-capsules."},{"key":"ref_43","first-page":"426","article-title":"Excipient choices for special populations","volume":"12","author":"Ko","year":"2013","journal-title":"Int. J. Pharm. Compd."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"738458","DOI":"10.3389\/fphar.2021.738458","article-title":"Orphan Drugs, Compounded Medication and Pharmaceutical Commons","volume":"12","author":"Hendrickx","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-017-0741-y","article-title":"Compounded medication for patients with rare diseases","volume":"13","author":"Dooms","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13023-019-1154-x","article-title":"Pharmaceutical compounding of orphan active ingredients in Belgium: How community and hospital pharmacists can address the needs of patients with rare diseases","volume":"14","author":"Vanhoorne","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1136\/annrheumdis-2020-217835","article-title":"Hydroxychloroquine shortages during the COVID-19 pandemic","volume":"80","author":"Mendel","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_48","unstructured":"FDA (2021, February 19). Current and Resolved Drug Shortages and Discontinuations Reported to FDA, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/drugshortages\/."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"l4627","DOI":"10.1136\/bmj.l4627","article-title":"Pricing of pharmaceuticals is becoming a major challenge for health systems","volume":"368","author":"Morgan","year":"2020","journal-title":"BMJ"},{"key":"ref_50","first-page":"60-CV3","article-title":"Hydroxychloroquine Sulfate 25 mg\/mL in Ora-Plus and Ora-Sweet SF","volume":"45","author":"Allen","year":"2020","journal-title":"U.S. Pharm."},{"key":"ref_51","first-page":"60","article-title":"Effects of Compounded Stanford Modified Oral Rinse (MucoLox) on the Survival and Migration of Oral Keratinocytes and Fibroblasts: Implications for Wound Healing","volume":"22","author":"Song","year":"2018","journal-title":"Int. J. Pharm. Compd."},{"key":"ref_52","first-page":"322","article-title":"Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)","volume":"21","author":"Ip","year":"2017","journal-title":"Int. J. Pharm. Compd."},{"key":"ref_53","first-page":"382","article-title":"Ursodiol 150 mg Capsules","volume":"7","author":"Allen","year":"2003","journal-title":"Int. J. Pharm. Compd."},{"key":"ref_54","first-page":"70","article-title":"Stability of Compounded Ursodiol Suspensions in PCCA Base, SuspendIt","volume":"23","author":"Pramar","year":"2019","journal-title":"Int. J. Pharm. Compd."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pec.2006.05.007","article-title":"The impact of patient participation on adherence and clinical outcome in primary care of depression","volume":"65","author":"Loh","year":"2007","journal-title":"Patient Educ. Couns."},{"key":"ref_56","first-page":"172","article-title":"Utilization and Costs of Compounded Medications for Commercially Insured Patients, 2012\u20132013","volume":"22","author":"McPherson","year":"2016","journal-title":"J. Manag. Care Sp\u00e9c. Pharm."},{"key":"ref_57","first-page":"159","article-title":"E-prescription errors and their resolution in a community compounding pharmacy","volume":"18","author":"Vasquez","year":"2014","journal-title":"Int. J. Pharm. Compd."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"42","DOI":"10.22159\/ijpps.2017v9i2.15681","article-title":"Extemporaneous compounding practice by pharmacists: A systematic review","volume":"9","author":"Kristina","year":"2017","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1331\/1544-3191.46.5.568.McPherson","article-title":"Prevalence of Compounding in Independent Community Pharmacy Practice","volume":"46","author":"McPherson","year":"2006","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_60","unstructured":"National Community Pharmacy Association (2012). Community Pharmacy-Compounding Survey, National Community Pharmacist Association."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/9\/1091\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:20:52Z","timestamp":1760142052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/9\/1091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":60,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ph15091091"],"URL":"https:\/\/doi.org\/10.3390\/ph15091091","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]}}}